Description
MODIFICATION INCORPORATES SECTION 5 OF EO 14398, CLAUSE 52.222-90, ADDRESSING DEI DISCRIMINATION
Base award description: NEW AWARD FOR FLUTICASONE/SALMETEROL INHALERS WITH GLAXOSMITHKLINE. ORDERING PERIOD IS AUGUST 1, 2026 - JULY 31, 2027 WIT FOUR ONE-YEAR OPTIONS.
Modification chain · 2 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2026-05-26+$0= $0
- Mod P000012026-08-31+$0= $0
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2026-05-26 | +$0 | $0 | NEW AWARD FOR FLUTICASONE/SALMETEROL INHALERS WITH GLAXOSMITHKLINE. ORDERING PERIOD IS AUGUST 1, 2026 - JULY… |
| Mod P00001· OTHER ADMINISTRATIVE ACTION | 2026-08-31 | +$0 | $0 | MODIFICATION INCORPORATES SECTION 5 OF EO 14398, CLAUSE 52.222-90, ADDRESSING DEI DISCRIMINATION |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI FRHTPHMZMX47)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C77024F0047 | NATIONAL CMOP OFFICE (36C770) · 6505 · DRUGS AND BIOLOGICALS | $3,166 | FY2024 |
| 36C24124F0121 | 241-NETWORK CONTRACT OFFICE 01 (36C241) · 6505 · DRUGS AND BIOLOGICALS | $39,180 | FY2024 |
| 36C24124F0119 | 241-NETWORK CONTRACT OFFICE 01 (36C241) · 6505 · DRUGS AND BIOLOGICALS | $33,793 | FY2024 |
| 36C24624N0685 | 246-NETWORK CONTRACTING OFFICE 6 (36C246) · 6505 · DRUGS AND BIOLOGICALS | $58,770 | FY2024 |
| 36C24624N0682 | 246-NETWORK CONTRACTING OFFICE 6 (36C246) · 6505 · DRUGS AND BIOLOGICALS | $19,590 | FY2024 |
| 36C24624N0687 | 246-NETWORK CONTRACTING OFFICE 6 (36C246) · 6505 · DRUGS AND BIOLOGICALS | $117,540 | FY2024 |
Other recipients under 6505 from NAC PHARMACEUTICALS (36E797) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36E79726A0025 | CHIESI USA INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0024 | NEUROTECH PHARMACEUTICALS, INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0023 | TAKEDA PHARMACEUTICALS AMERICA, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726D0041 | GOLDEN STATE MEDICAL SUPPLY, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0022 | AURINIA PHARMA US INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_IDV_36E79726D0030_3600 · retrieved 2026-09-26.